Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. reports developments as a clinical-stage pharmaceutical company focused on pain and central nervous system therapeutics designed to reduce opioid abuse and overdose risk. Its recurring updates center on the TAAP™ (Trypsin-Activated Abuse Protection) prodrug platform, the MPAR® (Multi-Pill Abuse Resistance) overdose-protection platform, and product candidates including PF614 and PF614-MPAR.
Company news also covers clinical-study progress, FDA-related designations and regulatory engagement, peer-reviewed data, scientific conference presentations, intellectual-property updates, financing transactions, financial results, Nasdaq compliance matters, board and governance changes, and strategic-review disclosures.
Ensysce Biosciences (NASDAQ:ENSC) announced it has enrolled 50% of subjects targeted for interim review in the pivotal Phase 3 PF614-301 trial as of January 28, 2026. Enrollment began in late December 2025 across three U.S. sites, with interim data expected after the planned review.
PF614 is a twice-daily, activation‑dependent opioid candidate engineered for extended pain relief with built-in abuse and tamper protection.
Ensysce Biosciences (NASDAQ:ENSC) announced on January 21, 2026 that the Brazilian Patent Office issued a Notice of Allowance for a patent (PI0919711-7) covering additional opioid families that use the company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.
The allowed patent includes both composition of matter and method of use claims, and the company says this expands its global intellectual property protection for next-generation analgesics, complementing existing allowances in North America, the EU, and South America. Management framed the development as strengthening its pain portfolio and advancing safer opioid formulations without compromising pain relief.
Ensysce Biosciences (NASDAQ:ENSC) received a Notice of Allowance from the European Patent Office for a patent covering PF8026, an immediate-release amphetamine prodrug using the company's TAAP™ and MPAR® technologies for built-in abuse and overdose protection. The allowed claims cover composition of matter and method of use, expanding Ensysce's ADHD portfolio alongside PF8001 (extended release). The release highlights that MPAR® overdose protection has been validated in clinical studies and cites a 2023 figure of ~3.9 million people aged 12+ who misused prescription stimulants, framing the program as addressing misuse and overdose risk.
Ensysce Biosciences (NASDAQ:ENSC) issued its 2025 annual shareholder letter outlining clinical, regulatory, IP and financing progress. Key 2025 achievements include initiation of the pivotal PF614-301 Phase 3 trial with enrollment started at two sites, FDA alignment on PF614 commercial manufacturing and CMC strategy, and advancement of PF614-MPAR under Breakthrough Therapy pathway. The company secured additional capital including a November 2025 $4M convertible preferred financing enabling access to up to $20M over 24 months and continued non-dilutive support from NIDA totaling over $25M for MPAR programs. A new MPAR patent allowance extends protection through 2042. Anticipated 2026 priorities include continued Phase 3 enrollment, further FDA interactions, MPAR labeling work, and PF9001 IND-enabling activities.
Ensysce Biosciences (NASDAQ:ENSC) announced the enrollment of the first patient in its pivotal Phase 3 trial of PF614 on December 9, 2025. The study, PF614-301, is a multicenter, randomized, double‑blind, placebo‑ and active‑controlled trial evaluating PF614 for moderate to severe pain after abdominoplasty.
The trial will test twice‑daily dosing intended to provide consistent post‑surgical analgesia while incorporating an innovative chemical mechanism designed to reduce abuse and overdose risk. Initial sites include CenExel JBR in Salt Lake City and CenExel Atlanta under principal investigators Dr. Todd Bertoch and Dr. Jessica McCoun.
Ensysce Biosciences (NASDAQ:ENSC) announced a U.S. Notice of Allowance for a new patent covering its MPAR® overdose protection technology, extending MPAR patent coverage through 2042. The patent titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof" includes composition-of-matter and method-of-use claims to strengthen the company’s IP estate. MPAR earned Breakthrough Therapy Designation from the FDA in January 2025. Clinical testing of PF614-MPAR reportedly showed effective pain relief when taken as prescribed and reduced excessive opioid delivery when multiple doses were taken. Ensysce is also applying MPAR to other drug classes and is conducting a second clinical trial to further evaluate the technology.
Ensysce Biosciences (NASDAQ:ENSC) announced on November 20, 2025 that the FDA provided written responses agreeing with Ensysce's proposed manufacturing approach for PF614, including regulatory starting materials and drug substance specifications.
The FDA feedback gives Ensysce a direct path to commercial production; commercial-scale manufacturing has been initiated with partner Purisys, LLC (a Noramco subsidiary). Management said the guidance supports scaling PF614, the company’s TAAP oxycodone analogue, toward market rollout for moderate-to-severe pain.
Ensysce Biosciences (NASDAQ:ENSC) closed a $4.0 million convertible preferred financing on November 17, 2025, with the potential for up to an additional $16.0 million in future tranches over the next 24 months (up to $20.0 million total).
The initial tranche carries a fixed conversion price of $2.50 per share, an alternate conversion based on average common stock prices, and 50% warrant coverage exercisable at the fixed conversion price for five years. Proceeds will accelerate the Phase 3 development of PF614 and support corporate initiatives, with management citing Phase 3 completion or market-readiness targets in the 18–24 month timeframe.
Ensysce Biosciences (NASDAQ:ENSC) reported Q3 2025 results and operational milestones on November 14, 2025. Key developments include the initiation of the pivotal Phase 3 PF614-301 trial in July 2025, FDA Breakthrough Therapy designation support for PF614-MPAR, and engagement of Rho, Inc. to run the pivotal study.
Financial highlights: cash $1.7M at Sept 30, 2025; completed a $4M convertible preferred stock financing in November with up to $16M additional tranches available; Q3 federal grant funding $0.5M (vs $3.4M a year ago); R&D $3.0M (Q3 2025) and net loss $3.7M (Q3 2025).
Ensysce Biosciences (NASDAQ:ENSC) released video highlights from its PAINWeek 2025 symposium titled "Pain Management, RE-Invented: A New Era for Analgesia", held in Las Vegas on September 3, 2025. The symposium featured medical and scientific leaders discussing challenges in pain treatment and Ensysce's proprietary platforms TAAP™ and MPAR®, which aim to reduce opioid misuse and overdose while preserving analgesia. Video highlights with expert commentary and real-world perspectives are available on the Ensysce Media/Science Center at www.ensysce.com.
The company said it continues advancing its portfolio toward commercialization with the goal of safer severe-pain management.